Fortress Biotech Inc. (FBIO)
Fortress Biotech Statistics
Share Statistics
Fortress Biotech has 29.53M shares outstanding. The number of shares has increased by 35.24% in one year.
| Shares Outstanding | 29.53M |
| Shares Change (YoY) | 35.24% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 23.06% |
| Shares Floating | 21.1M |
| Failed to Deliver (FTD) Shares | 1.37K |
| FTD / Avg. Volume | 0.47% |
Short Selling Information
The latest short interest is 3.63M, so 13.16% of the outstanding shares have been sold short.
| Short Interest | 3.63M |
| Short % of Shares Out | 13.16% |
| Short % of Float | 15.9% |
| Short Ratio (days to cover) | 12.24 |
Valuation Ratios
The PE ratio is -0.92 and the forward PE ratio is -3.64. Fortress Biotech's PEG ratio is 0.01.
| PE Ratio | -0.92 |
| Forward PE | -3.64 |
| PS Ratio | 0.73 |
| Forward PS | 0.2 |
| PB Ratio | 1.86 |
| P/FCF Ratio | -0.44 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Fortress Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 3.31.
| Current Ratio | 1.27 |
| Quick Ratio | 1.06 |
| Debt / Equity | 3.31 |
| Debt / EBITDA | -0.72 |
| Debt / FCF | -0.79 |
| Interest Coverage | -9.53 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $571.04K |
| Profits Per Employee | $-455.42K |
| Employee Count | 101 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 0.18 |
Taxes
| Income Tax | 312K |
| Effective Tax Rate | -0.26% |
Stock Price Statistics
The stock price has increased by -11.17% in the last 52 weeks. The beta is 1.83, so Fortress Biotech's price volatility has been higher than the market average.
| Beta | 1.83 |
| 52-Week Price Change | -11.17% |
| 50-Day Moving Average | 1.61 |
| 200-Day Moving Average | 1.8 |
| Relative Strength Index (RSI) | 51.5 |
| Average Volume (20 Days) | 292.05K |
Income Statement
In the last 12 months, Fortress Biotech had revenue of 57.67M and earned -46M in profits. Earnings per share was -2.21.
| Revenue | 57.67M |
| Gross Profit | 55.13M |
| Operating Income | -110.38M |
| Net Income | -46M |
| EBITDA | -104.49M |
| EBIT | -108.95M |
| Earnings Per Share (EPS) | -2.21 |
Balance Sheet
The company has 57.26M in cash and 75.33M in debt, giving a net cash position of -18.07M.
| Cash & Cash Equivalents | 57.26M |
| Total Debt | 75.33M |
| Net Cash | -18.07M |
| Retained Earnings | -740.87M |
| Total Assets | 144.22M |
| Working Capital | 18.97M |
Cash Flow
In the last 12 months, operating cash flow was -80.19M and capital expenditures -15M, giving a free cash flow of -95.19M.
| Operating Cash Flow | -80.19M |
| Capital Expenditures | -15M |
| Free Cash Flow | -95.19M |
| FCF Per Share | -4.58 |
Margins
Gross margin is 95.59%, with operating and profit margins of -191.38% and -79.75%.
| Gross Margin | 95.59% |
| Operating Margin | -191.38% |
| Pretax Margin | -209% |
| Profit Margin | -79.75% |
| EBITDA Margin | -181.17% |
| EBIT Margin | -191.38% |
| FCF Margin | -165.05% |
Dividends & Yields
FBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for FBIO is $21, which is 1220.8% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21 |
| Price Target Difference | 1220.8% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Oct 10, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 10, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -8.92 |
| Piotroski F-Score | 1 |